<DOC>
	<DOCNO>NCT02955420</DOCNO>
	<brief_summary>Berlin Cures develop BC 007 treat patient suffer disease ( chronic heart failure , pulmonary hypertension , chronic fatigue syndrome etc . ) associate functional autoantibody ( AAB ) direct G-protein coupled receptor ( GPCR ) . The first part study ( part A ) design evaluate safety tolerability ascend dos BC 007 . The study part blind placebo control order well discriminate possible safety signal . The assessment safety tolerability elderly cohort bridge dose elderly GPCR AAB positive subject part B . The subject part A confirm GPCR AAB negative . The objective second part study ( part B ) evaluate efficacy BC 007 neutralize AAB GPCR shortly dose compare baseline find optimal dose neutralization AAB individual . This dose shall take progress Phase II/III trial beta1-adrenergic receptor-AAB positive patient suffer chronic heart failure .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Efficacy BC 007 Healthy Subjects</brief_title>
	<detailed_description>Part A Primary objective : - To assess safety tolerability BC 007 single ascend intravenous ( i.v . ) bolus + infusion healthy , young elderly subject . Secondary objective : - To determine pharmacokinetic plasma urine profile BC 007 healthy , young elderly subject . Part B Primary objective : - To assess neutralizing potency BC 007 GPCR autoantibody alpha -1 adrenergic receptor , beta-1 adrenergic receptor , beta-2 adrenergic receptor endothelin-A-receptor follow ascend i.v . bolus + infusion . Secondary objective : - To assess safety tolerability BC 007 single ascend i.v . bolus + infusion GPCR AAB ( α ( 1 ) -adrenergic receptor AAB , ß ( 1 ) -adrenergic receptor AAB , ß ( 2 ) -adrenergic receptor AAB endothelin-A-receptor AAB ) positive healthy elderly subject . - To determine pharmacokinetic plasma urine profile BC 007 GPCR AAB ( α ( 1 ) -adrenergic receptor AAB , ß ( 1 ) -adrenergic receptor AAB , ß ( 2 ) -adrenergic receptor AAB endothelin-A-receptor AAB ) positive healthy elderly subject .</detailed_description>
	<criteria>Inclusion Criteria ( main ) : 1 . The subject healthy , male , nonsmoker slight/occasional smoker ( less equal 10 cigarette per day ) , 18 45 year age ( Cohorts 1 3 , Part A ) . 2 . The subject healthy , male female , nonsmoker slight/occasional smoker ( less equal to10 cigarette per day ) , 55 70 year age ( Cohort 4 [ Part A ] Part B ) . 3 . Female subject postmenopausal ( verified appropriate serum FSH level amenorrhea least one year ) . 4 . The subject body mass index ( BMI ) range 18.5 29.9 kg/m2 inclusive , ( healthy young male well elderly subject ) weigh least 50 kg &lt; 100 kg . 5 . The subject positive either one combination GPCR α ( 1 ) adrenergic receptor AAB , ß ( 1 ) adrenergic receptor AAB , ß ( 2 ) adrenergic receptor AAB endothelinAreceptor AAB ( Part B ) ( pre ) screen prior enrolment . 6 . The subject negative GPCR α ( 1 ) adrenergic receptor AAB , ß ( 1 ) adrenergic receptor AAB , ß ( 2 ) adrenergic receptor AAB endothelinAreceptor AAB ( pre ) screen prior enrolment ( Part A ) . 7 . Coagulation variable , uric acid , ALT , AST , alkaline phosphatase ( ALP ) , GGT , bilirubin creatinine must within normal laboratory reference range screen . 8 . Thyroidstimulating hormone ( TSH ) must within normal laboratory reference range screening . Exclusion Criteria ( main ) : 1 . Any history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic ( specifically gout ) , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge Investigator . 2 . Any history current intake beta blocker . 3 . Any history allergic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Autoantibodies</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Fatigue Syndrome , Chronic</keyword>
	<keyword>Idiopathic Pulmonary Hypertension</keyword>
	<keyword>Cardiomyopathies</keyword>
</DOC>